TiGenix CEO Confident Of European Green Light For Lead Asset
Executive Summary
TiGenix CEO Eduardo Bravo outlines group's commercialization plans for CPF candidate Cx601 in Europe and the US.
You may also be interested in...
Takeda Gets Serious About Cell Therapy With TiGenix Buy
Takeda will acquire its Belgian biotech partner, TiGenix, to strengthen its gastro-intestinal portfolio, bolster its regenerative medicines capacity and grow its US specialty care presence.
Orphans Dominate Products Seeking End-Of-Year Joy From CHMP
Five of the nine products that could this week be recommended for EU approval have orphan designation. The final meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.